CellsBin has closed a Series A financing led by 108 BioCapital to accelerate commercialization of its Rare-Cell Intelligence platform. The company did not disclose how much it raised.
CellsBin is developing what it calls Rare-Cell Biology, an approach intended to identify and analyze extremely rare cells that can provide information about disease progression, treatment response and patient outcomes.
Its Rare-Cell Intelligence platform combines microfluidics, patented multimodal imaging, single-cell analysis and artificial intelligence.
The platform is designed to detect rare cells, profile their characteristics, monitor biological changes over time, and analyze proprietary datasets using AI.
CellsBin believes these capabilities can give researchers and clinicians information conventional methods may miss, especially when biologically important cells exist only in very small numbers.
The company’s initial commercial and research applications focus on monitoring cell and gene therapies and hematologic cancers.
Over time, CellsBin seeks to establish Rare-Cell Biology as a broader discipline spanning research, drug development, and clinical medicine.
The Series A proceeds will support increased commercial adoption, strategic and channel partnerships, research and product development, expansion of clinical evidence and growth of the company’s scientific, technical and commercial teams.
KEY QUOTES:
“CellsBin is building a differentiated platform at the intersection of single-cell biology, artificial intelligence and translational medicine. Its ability to detect and characterize extremely rare cells could unlock important insights into therapeutic response, disease progression and patient outcomes. We have been impressed by Ali and the CellsBin team’s scientific rigor, platform vision and commitment to translating complex biology into actionable intelligence.”
Sasha Bakhru, Managing Partner of 108 BioCapital
“We are excited to partner with CellsBin and support the company as it expands its network of strategic, clinical and commercial relationships. We are already seeing strong interest from leading healthcare institutions in CellsBin’s technology and its potential to create meaningful clinical impact. We believe the 108 BioCapital ecosystem can help accelerate the company’s next phase of growth.”
Shahryar Oveissi, General Partner of 108 BioCapital
“This financing represents an important milestone in our mission to make rare cells visible, measurable and clinically actionable. 108 BioCapital shares our conviction that rare cells contain critical biological information that can enable earlier, more precise and more confident decisions. This partnership will help us advance the Rare-Cell Intelligence Platform, deepen our market and channel reach, and build the capabilities required to establish Rare-Cell Biology as a new foundation for understanding disease and therapeutic response.”
Ali Kabiri, Ph.D., Co-Founder and Chief Executive Officer of CellsBin
